OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ferguson on the Impact of the LACC Trial Data on Cervical Cancer Surgery

November 1st 2019

Sarah Ferguson, MD, discusses how the results from the LACC trial, which compared minimally invasive surgery with open surgery in patients with IA1, IA2, or IB1 cervical cancer, are impacting surgery in the cervical cancer field.

Dr. Abou-Alfa on the Results of the ClarIDHy Trial in Advanced Cholangiocarcinoma

November 1st 2019

Ghassan K. Abou-Alfa, MD, discusses the results of the phase III ClarIDHy trial in advanced cholangiocarcinoma.

Dr. Domchek on Results of the MEDIOLA Trial in BRCA-Mutated Metastatic Breast Cancer

November 1st 2019

Susan Domchek, MD, discusses the results of the phase II MEDIOLA trial in germline BRCA-mutated metastatic breast cancer.

Dr. Mok on Overall Survival Data From the ALEX Trial in ALK+ Lung Cancer

November 1st 2019

Tony S. K. Mok, MD, BMSc, FRCPC, discusses overall survival from the phase III ALEX trial in ALK-positive lung cancer.

Dr. Cohen on the DREAMM-2 Trial in Multiple Myeloma

October 31st 2019

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.

Dr. Mateos on Posthoc Analysis of ARROW Study in Multiple Myeloma

October 31st 2019

María-Victoria Mateos, MD, PhD, discusses the rationale for the posthoc analysis of the phase III ARROW study in multiple myeloma.

Dr. Usmani on CAR T Cells, Bispecific Antibodies, and ADCs in Multiple Myeloma

October 31st 2019

Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.

Dr. Kerrigan on Remaining Challenges in ROS1+ NSCLC

October 31st 2019

Katie Kerrigan, MD, discusses remaining challenges in the treatment of patients with ROS1-positive non–small cell lung cancer.

Dr. Saba on Immunotherapy/Radiation Combo in Head and Neck Cancer

October 31st 2019

Nabil F. Saba, MD, FACP, discusses the potential benefit of immunotherapy in combination with radiation in head and neck cancer.

Dr. Kumar on Implications of BELLINI Trial in Relapsed/Refractory Multiple Myeloma

October 31st 2019

Shaji K. Kumar, MD, discusses the takeaways from the phase III BELLINI trial which tested venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr. Mohler on Guidelines for Recording Family History in Prostate Cancer

October 31st 2019

James Mohler, MD, discusses what information should be included in a family history, based on the updated National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.

Dr. Rugo on Rationale for the ELAINE Study in ESR1-Mutated ER+/HER2- Breast Cancer

October 31st 2019

Hope S. Rugo, MD, discusses the rationale for the phase II ELAINE study with lasofoxifene in patients with ESR1-mutated, estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Borrello Sheds Light on the Multiple Myeloma Treatment Paradigm

October 31st 2019

Ivan M. Borrello, MD, discusses the current multiple myeloma treatment paradigm.

Dr. Powles on Design and Findings of the BISCAY Trial in Platinum-Refractory Urothelial Cancer

October 31st 2019

Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the design and findings of the phase Ib BISCAY trial in platinum-refractory urothelial cancer.

Dr. Gadgeel on the Results of the BFAST Trial in ALK+ Lung Cancer

October 31st 2019

Shirish M. Gadgeel, MD, MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, professor, Department of Internal Medicine, Division of Hematology/Oncology, co-leader, Thoracic Oncology Research Program, and associate director, Networking and Affiliated Centers, University of Michigan Medicine, discusses the results of the phase II/III BFAST trial in patients with ALK-positive lung cancer.

Dr. Saba on Anticipated Research in Head and Neck Cancer

October 31st 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, and professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses anticipated research in head and neck cancer.

Dr. Eward on FDA Approval of Pexidartinib in TGCT

October 30th 2019

William Eward, MD, DVM, discusses the approval of pexidartinib to treat patients with tenosynovial giant cell tumor.

Dr. Cristofanilli on Aromatase Inhibitor Adverse Events in Breast Cancer

October 30th 2019

Massimo Cristofanilli, MD, discusses adverse events caused by the use of aromatase inhibitors in breast cancer.

Dr. Low on Osimertinib Versus Dacomitinib in EGFR-Mutant NSCLC

October 30th 2019

Clarke A. Low, MD, discusses osimertinib (Tagrisso) versus dacomitinib (Vizimpro) in EGFR-mutant non–small cell lung cancer.

Dr. Burns on Identifying Genetic Alterations in Lung Cancer

October 30th 2019

Timothy F. Burns, MD, PhD, discusses methods of identifying genetic alterations in lung cancer.